---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-059327"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:07:50.517713+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akebia prices 25M-share public offering at $2.00/share, expects $46.5M net proceeds

## Summary
- Underwritten public offering of 25M shares at $2.00/share; gross proceeds $50M.
- Net proceeds ~$46.5M (or ~$53.6M if underwriters' option exercised in full).
- Underwriters granted 30-day option to purchase up to 3.75M additional shares.
- Expected closing March 21, 2025; Leerink Partners and Piper Sandler lead.
- Company states it is financed to achieve profitability under current operating plan.

## SEC filing metadata
- accession: 0001193125-25-059327
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312525059327/0001193125-25-059327-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312525059327/d908870d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-059327
- JSON: https://secwatch.observer/filing/0001193125-25-059327.json
- Plain text: https://secwatch.observer/filing/0001193125-25-059327.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.